BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21219570)

  • 1. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival.
    Smith JD; Banner NR; Hamour IM; Ozawa M; Goh A; Robinson D; Terasaki PI; Rose ML
    Am J Transplant; 2011 Feb; 11(2):312-9. PubMed ID: 21219570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
    Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
    J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival.
    Irving C; Carter V; Parry G; Hasan A; Kirk R
    Pediatr Transplant; 2011 Mar; 15(2):193-7. PubMed ID: 21199210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation.
    Safavi S; Robinson DR; Soresi S; Carby M; Smith JD
    J Heart Lung Transplant; 2014 Dec; 33(12):1273-81. PubMed ID: 25130554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation.
    Smith JD; Ibrahim MW; Newell H; Danskine AJ; Soresi S; Burke MM; Rose ML; Carby M
    J Heart Lung Transplant; 2014 Oct; 33(10):1074-82. PubMed ID: 24954882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.
    Clerkin KJ; Farr MA; Restaino SW; Zorn E; Latif F; Vasilescu ER; Marboe CC; Colombo PC; Mancini DM
    J Heart Lung Transplant; 2017 May; 36(5):540-545. PubMed ID: 27916323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation.
    Irving CA; Carter V; Gennery AR; Parry G; Griselli M; Hasan A; Kirk CR
    J Heart Lung Transplant; 2015 Oct; 34(10):1310-7. PubMed ID: 26123951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver.
    Abu-Elmagd KM; Wu G; Costa G; Lunz J; Martin L; Koritsky DA; Murase N; Irish W; Zeevi A
    Am J Transplant; 2012 Nov; 12(11):3047-60. PubMed ID: 22947059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?
    Moayedi Y; Fan CS; Tinckam KJ; Ross HJ; McCaughan JA
    Clin Transplant; 2018 Nov; 32(11):e13416. PubMed ID: 30276870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
    Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
    Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
    Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
    Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation.
    Hassan S; Regan F; Brown C; Harmer A; Anderson N; Beckwith H; Roufosse CA; Santos-Nunez E; Brookes P; Taube D; Willicombe M
    Am J Transplant; 2019 Jun; 19(6):1720-1729. PubMed ID: 30582278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.
    Kaneku H; O'Leary JG; Banuelos N; Jennings LW; Susskind BM; Klintmalm GB; Terasaki PI
    Am J Transplant; 2013 Jun; 13(6):1541-8. PubMed ID: 23721554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
    Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
    Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing.
    Süsal C; Wettstein D; Döhler B; Morath C; Ruhenstroth A; Scherer S; Tran TH; Gombos P; Schemmer P; Wagner E; Fehr T; Živčić-Ćosić S; Balen S; Weimer R; Slavcev A; Bösmüller C; Norman DJ; Zeier M; Opelz G;
    Transplantation; 2015 Sep; 99(9):1976-80. PubMed ID: 25769065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.